Viromed Medical AG Predicts Over 500% Revenue Growth by 2026

Frankfurt, Monday, 30 June 2025.
Viromed Medical AG forecasts a surge in revenue from EUR 1.37 million in 2024 to approximately EUR 80 million by 2026, driven by acquisitions and new product launches.
Strategic Initiatives and Market Position
Viromed Medical AG (‘Viromed’; ISIN: DE000A3MQR65), a pioneer in cold plasma technology, has announced a significant revenue expansion from approximately EUR 1.37 million in 2024 to an estimated EUR 80 million by 2026. This represents an anticipated growth of over 500% 5739.416 by 2026. The company’s growth strategy is shaped by strategic acquisitions and partnerships, particularly the acquisition of Pharmedix GmbH, which is expected to contribute considerably to the company’s 2025 revenue projections [1].
Innovative Product Launches
Viromed Medical AG plans to augment its product line with the launch of two innovative medical products, ViroCAP® and PulmoPlas®. These products are designed to leverage Viromed’s advanced cold plasma technology, targeting significant medical applications including infection protection and wound healing. The ViroCAP® product is particularly noteworthy as it is slated for customer delivery starting September 2025 [1]. The company expects these new offerings to substantially impact its revenue growth in 2026 [1][3].
Financial Outlook and Market Expansion
The financial outlook for Viromed is robust, with expectations of a slightly positive financial result in 2025 and an EBIT margin reaching double digits by 2026. This optimism is further supported by the company’s aggressive expansion plans into the North American market by the end of 2025 [3]. Such strategic moves are critical as Viromed seeks to solidify its market presence and extend the reach of its proprietary technologies beyond the DACH region [3].
Broader Industry Trends
Viromed Medical AG’s projected growth aligns with broader trends in the healthcare sector, where there is increasing demand for technologically advanced medical solutions. The company’s strategy of focusing on transforming patient outcomes through cutting-edge technology has positioned it to capture emerging opportunities in the market. The healthcare sector is expected to significantly benefit from Viromed’s ongoing innovations and collaborations [3].